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Abstract
Background: Streptococcus pneumoniae is a leading cause of morbidity and mortality in the elderly. To prevent
invasive pneumococcal diseases, the 23-valent pneumococcal polysaccharide vaccine (PPV) is recommended in
subjects over 65 years of age. Although it has been reported to provide approximately 50-80% protection against
invasive disease in the general elderly population, there is still controversy as to the effectiveness of the PPV in the
elderly.
Methods: To evaluate the immune response to the pneumococcal polysaccharide vaccine in the elderly, samples
from young adults and elderly were obtained before and one month after vaccination. The quantitative and
qualitative response to the vaccine were measured by the ELISA and opsonophagocytic killing assay for eight
vaccine type serotypes (4, 6B, 9V, 14, 18C, 19A, 19F, 23F) and one vaccine-related serotype (6A).
Results: The response to the pneumococcal polysaccharide vaccine showed a similar response between adults
and elderly when evaluated by the ELISA, however the functional activity of the antibodies elicited after
vaccination were lower in the elderly group for more than half of the serotypes evaluated. In comparison of the
antibody needed for 1:8 opsonic titer, more antibodies were needed in the elderly for serotypes Pn 4, 19F, 23F and
6A, suggesting the functional activity of antibody detected by the ELISA was lower in the elderly compared with
the adult group for these serotypes. As for subjects with an opsonic titer <8 after vaccination, only one subject
each for serotypes Pn 4, 9V and 6A were found in the adult group. However, up to 10 (30.3%) of the subjects did
not show opsonic activity after vaccination in the elderly group for serotypes Pn 4, 9V, 14, 19A and 6A.
Conclusions: Although the amount of antibodies elicited were similar between the two age groups, distinct
differences in function were noted. This report highlights the importance of a quantitative and qualitative
evaluation of the immunogenic response to the PPV in the elderly age group.
Trial registration: This trial is registered with Clinical trials.gov. Registration number NCT00964769
Background
Streptococcus pneumoniae is an important pathogen
worldwide causing infection of the respiratory tract, bac-
teremia, and meningitis and a leading cause of morbidity
and mortality in young children and the elderly. To pre-
vent invasive pneumococcal diseases, the 23-valent
pneumococcal polysaccharide vaccine (PPV) is recom-
mended in subjects aged 65 years and over [1]. It pro-
vides approximately 50-80% protection against invasive
disease in the general elderly population [2], although
there is still controversy as to the effectiveness of the
PPV in the elderly [3,4].
While the effectiveness of vaccine can be demon-
strated by clinical studies directly, clinical studies may
not be easy to perform. An alternative to clinical studies
is to assess the immune responses to vaccine, ‘as u r r o -
gate of protection’. For the pneumococcal vaccine eva-
luation, the concentration of type specific antibody
measured with enzyme-linked immunosorbent assay
(ELISA) has been applied. However, many observations
indicate that the antibody’s ability to enhance opsono-
phagocytosis should be the preferred measure of pneu-
mococcal vaccine-induced immunity [5].
In the elderly, the immune response of PPV measured
with ELISA is as much as that in young adults [6-9].
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elderly; the previously used 2
nd generation ELISA is
known to show little specificity due to cross-reaction with
contaminants in the capsular polysaccharide (PS), and
although the method has gone through improvements
[10-13], nonfunctional antibodies can be detected. Also,
there is possibility that the elderly may produce pneumo-
coccal antibodies with sufficient avidity to bind capsular
PS adsorbed on ELISA plates, but with insufficient avidity
to induce opsonophagocytosis [6], result in producing
antibodies that are less opsonic than those produced by
young adults. But there are few reports of the opsonic
function after the vaccine in the elderly [6,14].
Therefore, to determine the immune response in the
elderly age group against the PPV, we performed the
ELISA and opsonophagocytic killing assay (OPKA) in
pre- and postvaccine sera. The response was compared
with healthy adults, which the effectiveness of the vac-
cine in healthy adults is already established [3,4]. The
response was evaluated for eight vaccine type serotypes
(4, 6B, 9V, 14, 18C, 19A, 19F, 23F) which are prevalent
serotypes of invasive diseases and to which the immuno-
genicity have been studied widely in various age groups
after the introduction of the 7-valent protein conjugate
pneumococcal vaccine. Also, due to the fact that cross-
protection for 6A in PPV vaccinated subjects has been
anticipated but not widely proved, the immune response
to the vaccine-related serotype 6A was evaluated.
Methods
Subjects and Sera Collection
The study group consisted of subjects over 65 years of
age and the control group included subjects under the
age of 45 years. The subjects in both age groups were
healthy volunteers. All subjects had no previous pneu-
mococcal vaccination history and exclusion criteria
included asplenia, cancer, liver or renal failure and his-
tory of hypersensitivity to vaccine. Vaccinees in both
groups were not immunocompromised and this study
did not include patients on chemotherapy, steroid or
immunomudulating treatment, diabetes mellitus, alco-
holism and chronic lung disease. Paired sera were col-
lected from all participants. Prevaccine sera were
obtained just before vaccination and postvaccine sera
were obtained 4-6 weeks following vaccination. Sera
were stored at -70°C until analysis.
The study protocol was approved by the Institutional
Review Board and was conducted in accordance with the
Declaration of Helsinki and Good Clinical Practice guide-
lines and written consent was obtained before enrollment.
Vaccine
All subjects received a single intramuscular injection
of 0.5 ml Pneumo23® (Sanofi-Aventis, Lyon France).
A 0.5 ml dose of PPV contains 25 micrograms of puri-
fied capsular polysaccharide from each of 23 serotypes
( 1 ,2 ,3 ,4 ,5 ,6 B ,7 F ,8 ,9 N ,9 V ,1 0 A ,1 1 A ,1 2 F ,1 4 ,1 5 B ,
17F, 18C, 19A, 19F, 20, 22F, 23F and 33F).
ELISA anti-PS IgG Antibody Concentrations
Anti-pneumococcal (Pn) antibodies against vaccine sero-
types 4, 6B, 9V, 14, 18C, 19F and 23F and vaccine-
related serotype 6A were measured by 3rd generation
ELISA using both C-PS and 22F serotype capsular PS
absorption, as previously described [10,13]. Briefly, each
well of a 96-well medium binding microtiter plate
(Corning Inc., Corning, NY) was coated with 100 μlo fa
serotype-specific pneumococcal PS antigen (American
Type Culture Collection [ATCC], Manassas, Va.) diluted
to a predetermined concentration (Serotype 6A PS was
a gift from G. Schiffman), and plates were incubated at
37°C for 5 hours in a humidified chamber. The coated
plates were washed with 1 × Tris-buffered saline with
0.01% Brij 35 solution. Test sera were preabsorbed with
C-PS (Statens Serum Institut, Copenhagen, Denmark)
and 22F capsular PS (ATCC), and the reference stan-
dard 89-SF (provided by Carl Frasch, Center for Biolo-
gics Evaluation and Research, Food and Drug
Administration, Bethesda, MD.) was preabsorbed with
C-PS. The pre-absorbed sera and 89-SF were serially
diluted 2.5-fold in absorption solution and incubated at
25°C for 30 minutes. After incubation, the sera (50 μl)
were transferred to the coated microtiter plates, and the
plates were incubated for 2 hours at 25°C. The plates
were washed 5 times, and 100 μl of diluted alkaline
phosphatase-conjugated goat anti-human IgG (Southern
Biotech, Birmingham, AL) was added to each well. After
2-hour incubation, the plates were washed 5 times, and
100 μl of substrate solution {diethanolamine (Sigma,
S t .L o u i s ,M O . )w i t h1m g / m lp-nitrophenyl phosphate
powder (Sigma)} was added to each well. After 2-hour
incubation at 25°C, 50 μl of 3 M NaOH was added to
all wells to stop the enzyme reaction. The optical den-
sity was measured at 405 nm and 690 nm using an
ELISA microplate reader. Optical densities were con-
verted to antibody concentrations using the CDC soft-
ware for pneumococcal ELISA (written by Brian
Plikaytis at the Centers for Disease Control and Preven-
tion, Atlanta, GA. It can be downloaded free of charge
from http://www.cdc.gov/ncidod/dbmd/bimb/elisa.htm).
A detailed protocol can be found at a website
http://www.vaccine.uab.edu.
Opsonophagocytic Killing Assay (OPKA)
The opsonic activities of the samples were evaluated by
a double-serotype OPKA, as previously described
[15,16]. Briefly, HL-60 cells were differentiated into
granulocytic cells by culturing them in RPMI 1640 with
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(Fisher Scientific, Pittsburgh, Pa.) for 5 days. After dif-
ferentiation, HL-60 cells were diluted to 10
7 cells/ml in
Hanks’ buffer supplemented with 0.1% gelatin and 10%
fetal calf serum. Test samples (serum) were also diluted
in the same buffer. Target strains expressing capsule
type 4, 6A, 6B, 9V, 14, 18C, 19A, 19F, 23F with antibio-
tic resistance to optochin or streptomycin were reported
(~2 × 10
5 cfu/ml of each serotype) [15]. Equal volumes
of two bacterial suspensions that were chosen to be ana-
lyzed together, were pooled. Ten microliters of pneumo-
coccal solution containing 1,000 CFU and 20 μlo ft e s t
sample were placed in each well of a 96-well microtiter
plate. After 30 min of incubation at 25°C, 40 μlo fH L -
60 cell suspension (4 × 10
5 cells per well) and 10 μlo f
baby rabbit complement (Pelfreeze, Browndeer, Wis.)
were added to each well. The mixture was incubated for
1 h at 37°C with shaking. Five microliters of the reaction
mixture was plated on two different Todd-Hewitt agar-
yeast extract plates. After the fluid was absorbed into
the agar, one plate was overlaid with molten Todd-
Hewitt agar (0.75%) containing yeast extract (0.5%), 0.5
mg of optochin/liter and 100 mg of TTC (Sigma)/liter
[15]. The other plate was overlaid with Todd-Hewitt
agar containing yeast extract, 100 mg of streptomycin/
liter, and TTC. After an overnight incubation in a can-
dle jar at 37°C, the number of bacterial colonies in the
agar plates was enumerated using an automated colony
counter. Opsonic titer was defined as the serum dilution
that kills 50% of bacteria and was determined by linear
interpolation.
Statisics
Geometric mean concentrations (GMCs) of anti-pneu-
mococcal IgG antibodies, geometric mean titers (GMT)
of opsonic titer, geometric mean potency (GMP) for
antibody potency and geometric mean indices (GMI) for
antibody needed for 1:8 opsonic titer were evaluated
and two-sided 95% confidence intervals (CIs) were
determined to each pneumococcal serotype. Serum sam-
ples with opsonic titer <8 were assigned a value of 4 for
analysis purposes. A two-tailed Mann-Whitney U-test
was used to analyze differences between pre and post
vaccine sera and between age groups. Reverse cumula-
tive distribution curves were used to display percentages
of subjects that achieved different opsonic titer or
potency to each of the pneumococcal serotypes.
Results
Subjects
Thirty-three subjects were enrolled in the elderly group.
The age of these subjects ranged from 65 to 70 years
(median 66 years). Among these subjects, 20 were male
and 13 were female.
The control group consisted of twenty-four adult sub-
jects under the age of 45 years, range from 24 to 37
years. Among these subjects, 13 were male and 11 were
female.
Specific Antibody Concentration by ELISA
The GMCs and 95% CIs for pre- and post-immune anti-
Pn IgG concentrations are shown in Table 1. After
immunization, the GMC increased significantly in seven
out of the eight serotypes evaluated in each age group.
Anti-Pn 6A IgG did not increase significantly, which is
not included in the PPV.
In a comparison of GMCs between the elderly and
adult groups, preimmune and postimmune GMCs did
not show a difference between age groups except for Pn
4 and 6A.
Antibody Function by OPKA
The GMTs and 95% CIs for pre- and postimmune opso-
nic titers are shown in Table 1. The GMT increased sig-
nificantly after immunization for all serotypes in both
the adult and elderly groups. OPKA was done in limited
patients for serotype Pn 14 due to lack of sera {Adults
(N = 10), Elderly (N = 20)}.
In the preimmune sera, no difference in GMT was
seen between the elderly and adult age groups. However,
after immunization, GMT was higher in the adult group
for four out of nine serotypes evaluated; Pn 4, 14, 19A
and 6A.
The reverse cumulative distribution curves for postim-
mune opsonic titers are shown in Fig. 1 and the data in
Table 2 present percentages of subjects who achieved
certain opsonic titers to each serotype.
Before immunization, the number of subjects with no
detectable opsonic activity( o p s o n i ct i t e r< 8 )r a n g e d
from 3 (12.5%) for Pn 23F to 17 (70.8%) for Pn 4 in the
adult group and 7 (21.2%) for Pn 14 to 27 (81.8%) for
Pn 4 in the elderly group. However after vaccination, in
the adult group, all subjects showed opsonic activity for
serotypes Pn 6B, 14, 18C, 19A, 19F and 23F. Whereas in
the elderly group, subjects with no detectable opsonic
activity were noted for serotypes Pn 4, 9V, 14, 19A and
6A {range 1 (3.0%) for Pn 9V to 10 (30.3%) for Pn 4}.
Number of subjects with no detectable opsonic activity
for each serotype is shown in Table 3. In the elderly
group, 2 (6.1%) subjects did not show detectable opsonic
activity for 3 serotypes and 2 (6.1%) subjects for 2
serotypes.
Antibody potency was measured by dividing the opso-
nic titer by the antibody concentration for each serotype
(Table 3) [8]. Although there was no difference in GMP
of specific antibody between the two age groups in the
preimmune sera (except for Pn 6A), after immunization,
antibody potency was significantly higher in the adult
Lee et al. BMC Infectious Diseases 2010, 10:60
http://www.biomedcentral.com/1471-2334/10/60
Page 3 of 8Table 1 Geometric means for antibody concentration and opsonization titers (Elderly, N = 33; Adults, N = 24)
Serotype Age Pre-IgG concentration (μg/mL) Post-IgG concentration (μg/mL) Pre-Opsonic titer (OT) Post-Opsonic titer (OT)
GMC 95% CI Sig GMC 95% CI Sig GMT 95% CI Sig GMT 95% CI Sig
4 Adult 0.43 0.32-0.59 P < 0.05 2.21 1.61-3.05 P < 0.05 17 6-47 NS 1300 694-2437 P < 0.05
Elderly 0.27 0.22-0.34 1.29 0.88-1.89 10 5-20 220 85-569
6B Adult 1.06 0.75-1.50 NS 6.17 3.51-10.85 NS 364 104-1270 NS 8023 5747-11202 NS
Elderly 1.17 0.85-1.61 7.73 4.13-14.48 175 65-473 5495 3823-7898
9V Adult 1.08 0.66-1.77 NS 6.05 4.22-8.68 NS 504 136-1867 NS 6380 3097-13140 P = 0.05
Elderly 0.71 0.51-0.99 5.54 3.62-8.49 229 81-649 4506 2654-7649
14
a Adult 3.02 1.56-5.86 NS 18.7 9.91-35.29 NS 237 71-795 NS 6036 4091-8907 P < 0.05
Elderly 1.92 1.26-2.93 10.12 6.47-15.83 579 192-1748 4673 2298-9501
18C Adult 1.10 0.72-1.67 NS 5.8 3.53-9.52 NS 675 236-1931 NS 7226 5167-10105 NS
Elderly 0.95 0.64-1.42 6.77 4.42-10.37 273 104-717 6698 4481-10012
19A Adult ND ND ND ND 59 21-170 NS 2995 1919-4675 P < 0.05
Elderly ND ND 27 12-58 556 252-1227
19F Adult 3.28 2.38-4.52 NS 8.42 5.42-13.1 NS 40 15-105 NS 2082 1409-3075 NS
Elderly 2.87 2.17-3.81 7.18 5.18-9.95 43 19-97 1183 759-1843
23F Adult 0.60 0.37-0.99 NS 3.22 1.91-5.41 NS 485 183-1286 NS 3101 2027-4746 NS
Elderly 0.70 0.48-1.01 5.8 3.64-9.23 269 111-653 3314 2152-5101
6A Adult 1.62 1.19-2.22 P < 0.05 2.39 1.78-3.21 NS 54 17-171 NS 2097 1041-4226 P < 0.05
Elderly 3.25 2.21-4.79 4.01 2.81-5.72 17 9-36 244 102-587
pre vs post P < 0.05
aFor Pn 14 OPKA was done in a limited patients due to lack of sera {Adults (N = 10), Elderly (N = 20)}
Figure 1 Reverse cumulative distribution curves for opsonic titers. Open Circle: Adults; Closed Circle: Elderly. * For Pn 14 OPKA was done in
limited patients due to lack of sera {Adults (N = 10), Elderly (N = 20)}.
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Page 4 of 8group for four out of eight serotypes, including Pn 4,
19F, 23F and 6A. The reverse cumulative distribution
curves for the postimmune antibody potency are shown
in Fig. 2.
Amount of antibody needed for 1:8 opsonic titer
(GMI) was evaluated by dividing the antibody concen-
tration (ng/ml) by the opsonic titer and multiplying by 8
(Table 3) [8]. There was no difference in measurements
between the age groups in the pre-vaccine sera. How-
ever, after vaccination, GMI was significantly higher in
the elderly group for serotypes Pn 4, 19F, 23F and 6A.
Discussion
After vaccination with PPV, although the amount of
antibodies elicited were similar between the two groups,
distinct differences in function were noted. After vacci-
nation, the opsonic activity was lower in the elderly
group against more than half of the serotypes evaluated.
Also, in the analysis for antibody needed for 1:8 opsoni-
zation, more antibodies were needed in the elderly for
s e r o t y p e sP n4 ,1 9 F ,2 3 Fa n d6 As u g g e s t i n gt h ef u n c -
tional activity of antibodies detected by the ELISA is
lower in the elderly compared with the adult group for
Table 2 Subjects with opsonic titer < 8 pre- and post-vaccination
Serotype Pre-vaccination Opsonic titer<8 Post-vaccination Opsonic titer<8
Adult (N = 24) n/(%) Elderly (N = 33) n/(%) Adult (N = 24) n/(%) Elderly (N = 33) n/(%)
4 17 (70.8%) 27 (81.8%) 1 (4.2%) 10 (30.3%)
6B 7 (29.2%) 11 (33.3%) 0 (0.0%) 0 (0.0%)
9V 7 (29.2%) 11 (33.3%) 1 (4.2%) 1 (3.0%)
14
a 7 (29.2%) 7 (21.2%) 0 (0.0%) 2 (6.1%)
18C 4 (16.7%) 8 (24.2%) 0 (0.0%) 0 (0.0%)
19A 11 (45.8%) 17 (51.5%) 0 (0.0%) 4 (12.1%)
19F 12 (50.0%) 14 (42.4%) 0 (0.0%) 0 (0.0%)
23F 3 (12.5%) 7 (21.2%) 0 (0.0%) 0 (0.0%)
6A 12 (50.0%) 21 (63.6%) 1 (4.2%) 7 (21.2%)
a For Pn 14 OPKA was done in a limited patients due to lack of sera {Adults (N = 10), Elderly (N = 20)}.
Table 3 Geometric means for antibody potency and antibody needed for 1:8 opsonization index (Elderly, N = 33;
Adults, N = 24)
Serotype Age Pre-Antibody potency
(OT/[IgG])
Post-Antibody potency
(OT/[IgG])
Pre-Antibody needed for 1:8
opsonization index (ng/ml)
Post-Antibody needed for 1:8
opsonization index (ng/ml)
GMP 95% CI Sig GMP 95% CI Sig GMI Sig GMI Sig
4 Adult 42 16-111 NS 633 372-1076 P < 0.05 191.4 NS 12.6 P < 0.05
Elderly 37 18-73 171 77-378 218.6 46.7
6B Adult 343 102-1153 NS 1349 743-2451 NS 23.3 NS 5.9 NS
Elderly 150 57-392 710 418-1209 53.5 11.3
9V Adult 458 145-1448 NS 1112 554-2233 NS 17.5 NS 7.2 NS
Elderly 324 126-834 813 466-1417 24.7 9.8
14
a Adult 63 23-172 NS 423 202-886 NS 126.1 NS 18.9 NS
Elderly 248 71-860 426 211-859 32.3 18.8
18C Adult 641 242-1699 NS 1440 951-2182 NS 12.5 NS 5.6 NS
Elderly 286 121-677 990 655-1497 28.0 8.1
19A Adult ND ND ND ND ND ND ND ND
Elderly ND ND ND
19F Adult 12 5-30 NS 276 195-391 P < 0.05 653.2 NS 29.0 P < 0.05
Elderly 15 7-31 165 128-212 535.7 48.5
23F Adult 789 309-2012 NS 982 650-1482 P < 0.05 10.1 NS 8.1 P < 0.05
Elderly 386 170-879 571 396-824 20.7 14.0
6A Adult 32 11-96 P < 0.05 888 444-1774 P < 0.05 249.1 P < 0.05 9.0 P < 0.05
Elderly 5 3-11 61 28-134 1486.5 131.3
pre vs post P < 0.05
a For Pn 14 OPKA was done in a limited patients due to lack of sera {Adults (N = 10), Elderly (N = 20)}.
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Page 5 of 8these serotypes. Moreover, whereas almost all subjects
showed detectable opsonic activity after vaccination in
the adult group, up to 10 (30.3%) of the subjects did not
show opsonic activity in the elderly group for serotypes
Pn 4, 9V, 14, 19A and 6A
Recently, Schenkein et al. reported the opsonic anti-
body response to the PPV in the elderly [14]. In the arti-
cle, the opsonic titer and antibody potency showed a
significant difference between young and old adults for
all 7 serotypes (Pn 4, 6B, 9V, 14, 18C, 19F and 23F)
evaluated. Our results showed functional differences for
6 out of 9 serotypes evaluated (Pn 4, 14, 19A, 19F, 23F
and 6A). The fact that the elderly subjects in our study
were fairly younger (range 65-70 years, median 66 years)
could be an explanation for difference in results. Func-
tional decrease in the activity of antibodies has been
reported to be more pronounced in the elderly as age
i n c r e a s e d[ 6 ] .A l s oi np r e v i o u sr e p o r t s ,t h ea n t i b o d y
titer after vaccination with PPV was better in male
elderly compared with females [7] and the majority of
the elderly subjects in our study were male.
T h ep r e v a c c i n ea n t i b o d yc oncentration and opsonic
titer were similar between the age groups. Also the
antibody needed for 1:8 opsonic titer was similar in
the prevaccine sera of the elderly and adults. This is
interesting considering rates and mortality from
pneumococcal diseases are higher in the elderly group.
This could be due to the fact that the subjects in this
study were 65-70 years (median 66 years) of age. How-
ever, the susceptibility of el d e r l yp e r s o n si sm u l t i f a c -
torial and nonimmunologic factors such as suppression
of gag reflex, underlying disease predominate, with
chronic cardiopulmonary and other diseases contribute
to this. Romero-Steiner et al. reported prevaccination
opsonic titers of elderly recipients to be lower when
compared with younger adults, where the subjects ran-
ged from age 63-103 years (mean 85.5 years) [6], but
the control group consisted of a limited number of
subjects (n = 12). Further research on older aged
elderly subjects would be desirable.
The results of our study reflect the effect of aging on
the B-cell immune system. In the elderly, the B cell pro-
duction rate decreases, however the number of periph-
eral B cells remain constant [17,18]. This is due to the
capacity of B cell for peripheral self-renewal and their
increased life span when new B cells are not produced.
However, whereas the magnitude of antibody response
to T-independent antigens is maintained during aging,
the quality of these antibodies alters during aging [19].
The change of affinity results from compromised selec-
tion of high affinity antibodies within the germinal cen-
ter [19,20].
Figure 2 Reverse cumulative distribution curves for antibody potency. Open Circle: Adults; Closed Circle: Elderly. * For Pn 14 OPKA was
done in limited patients due to lack of sera {Adults (N = 10), Elderly (N = 20)}.
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Page 6 of 8In this study, we evaluated the response to the vac-
cine-related serotype Pn 6A. The prevaccine anti-Pn 6A
antibody concentration seemed to be higher in the
elderly, however after vaccination, the opsonic titer was
significantly higher in the adult group. Also, the anti-
body needed for 1:8 opsonic titer was more than 14
times higher in the elderly group. Although a cross-
reactive immune response was elicited to Pn 6A in both
groups, a much weaker response was seen in the elderly.
P n6 Ai sn o ti n c l u d e di nt h eP P V .O n l yP n6 Bw a s
included in the PPV because antibodies to the two sero-
types were thought to be highly cross-reactive, and Pn
6B is a more stable antigen [21]. The striking difference
between age groups in immunogenic response to Pn 6A
was an interesting finding which suggests with vaccina-
tion of PPV in the elderly, the effectiveness towards
pneumococcal diseases by serotype Pn 6A might be
lower compared with the adults. Also, recently a new
serotype Pn 6C has been discovered and considering
reports on increase of Pn 6C in all age groups after rou-
tine immunization in children of the 7-valent pneumo-
coccal vaccine are accumulating, close monitoring on
the epidemiologic changes of these serotypes in the
elderly is desirable [22-24].
Previous reports on the immunogenicity to the PPV in
the elderly group show adequate mean immune
responses, good antibody fold increase and comparable
IgG antibody avidity with adults [7,8,25-27]. These
reports are based on immunogenicity evaluated by
ELISA. However, clinical data show various results
related to the effectiveness of the vaccine, which leads
us to acknowledge the need for additional methods of
evaluation of the response to the vaccine.
Discrepancy between antibody function and antibody
concentration in a clinical setting has been reported [6].
A passive-protection experiment in mice with S. pneu-
monia compared protection from two different sera
with the same antibody concentration but different
opsonic titers and antibody avidity. The serum with
high opsonic titer and antibody avidity showed 100%
protection whereas no protection was observed with a
serum with the same antibody concentration but low
opsonic titer and antibody avidity. These results empha-
size the importance of evaluation of antibody concentra-
tion and antibody function. Although the OPKA has
been known as a labor intensive method, OPKA meth-
ods have been evolving rapidly and is now capable of
evaluating multiple serotypes for many samples with
only small amounts of sera [16,28-31].
This report highlights the importance of a quantitative
and qualitative evaluation in this age group. There was a
definite overall increase in opsonic titers after vaccina-
tion for all serotypes in the elderly, thus the recommen-
dations for vaccination in the elderly should not be
discouraged. Also, recently many countries have shown
the cost-effectiveness of routine vaccination of PPV in
the elderly [32,33]. However, due to the fact that the
response in the elderly was weaker for some serotypes
and individuals compared with adults, we emphasize the
need of evaluation of functional activity within this age
group when determining the immunogenic response.
Also, with the vigorous development of pneumococcal
vaccines, efforts to enhance this weaker response in this
age group are warranted. Therefore, the results of this
article could be invaluable in the development of the
optimal vaccine and making decisions for the proper
policy for pneumococcal vaccination in the elderly.
Conclusions
After vaccination with PPV, although the amount of
antibodies elicited were similar between the two groups,
distinct differences in function were noted. The immu-
nogenic response to the PPV vaccine should be evalu-
ated by the quantitative and qualitative response in this
age group.
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